{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-105002","form_type":"8-K","ticker":"DNTH","cik":"0001690585","company_name":"Dianthus Therapeutics, Inc. /DE/","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.675250+00:00","generated_at":"2026-05-17T17:50:01.860552+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Dianthus Q2 net loss $31.6M ($0.88/sh); cash $309.1M; gMG Ph2 data due Sept","bullets":["Cash, cash equivalents and investments $309.1M as of June 30, 2025; runway into 2H 2027.","Net loss $31.6M ($0.88 basic/diluted EPS) vs $17.6M ($0.51) in Q2 2024.","R&D expenses $26.3M (incl. $2.5M stock-based) vs $18.1M; increase driven by Phase 2/3 costs.","Top-line Phase 2 MaGic trial results for claseprubart in gMG anticipated September 2025.","Phase 3 CAPTIVATE CIDP trial on track; interim responder analysis expected 2H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-105002","json":"https://secwatch.observer/filing/0000950170-25-105002.json","markdown":"https://secwatch.observer/filing/0000950170-25-105002.md","text":"https://secwatch.observer/filing/0000950170-25-105002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690585/000095017025105002/0000950170-25-105002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690585/000095017025105002/dnth-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:50:01.860552+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}